A carregar...
Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects
Hydroxyurea (HU), an FDA-approved drug for treating sickle cell disease, is used as an antitumor drug alone and together with conventional chemotherapeutics or radiation therapy. HU is used primarily to treat myeloproliferative diseases because it inhibits the enzyme ribonucleotide reductase involve...
Na minha lista:
| Publicado no: | iScience |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8215227/ https://ncbi.nlm.nih.gov/pubmed/34189437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2021.102673 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|